Spring Bank Pharmaceuticals (NASDAQ:SBPH) Issues Quarterly Earnings Results, Beats Estimates By $0.28 EPS

Spring Bank Pharmaceuticals (NASDAQ:SBPH) released its quarterly earnings results on Wednesday. The company reported ($0.28) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.28, Fidelity Earnings reports.

NASDAQ SBPH traded down $0.17 during trading on Friday, hitting $4.49. The stock had a trading volume of 66,995 shares, compared to its average volume of 60,839. The company has a debt-to-equity ratio of 0.06, a current ratio of 12.11 and a quick ratio of 12.11. The stock has a market cap of $73.83 million, a PE ratio of -2.40 and a beta of 0.37. Spring Bank Pharmaceuticals has a one year low of $3.58 and a one year high of $15.00. The firm’s 50 day moving average price is $4.57.

In other news, insider Martin J. Driscoll acquired 5,000 shares of the firm’s stock in a transaction on Tuesday, May 21st. The stock was acquired at an average price of $6.63 per share, with a total value of $33,150.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Martin J. Driscoll acquired 10,000 shares of the firm’s stock in a transaction on Wednesday, May 29th. The stock was purchased at an average cost of $6.03 per share, with a total value of $60,300.00. The disclosure for this purchase can be found here. In the last three months, insiders acquired 32,000 shares of company stock valued at $169,530. 15.60% of the stock is owned by insiders.

Several research analysts recently commented on SBPH shares. Chardan Capital set a $25.00 price target on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, April 12th. ValuEngine upgraded Spring Bank Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday. Piper Jaffray Companies dropped their price target on Spring Bank Pharmaceuticals from $25.00 to $10.00 and set an “overweight” rating for the company in a research report on Monday, July 1st. Dawson James reiterated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research report on Monday, May 13th. Finally, Cantor Fitzgerald set a $29.00 price target on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, April 12th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Spring Bank Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $19.30.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).

Read More: What is a management fee?

Earnings History for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.